Loading stock data…
EyePoint (EYPT)
$4.56-0.02 (-0.44%)
Market ClosedLast close Sep 8
EyePoint, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
EyePoint, Inc. in the Healthcare sector is trading at $4.56 with a market capitalization of $1.0B. Wall Street consensus targets $25.91 (11 analysts), implying a +468.2% move over the next 12 months. The stock is currently near its 52-week low of $3.95, remaining 66.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +468.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $507,000↓ | $696,000↑ | $620,000↓ | $966,000↓ | $5.33M |
| Gross Profit | $507,000↑ | $168,000↓ | $245,000 | $245,000↓ | $5.17M |
| Operating Income | -$97.38M↓ | -$87.23M↓ | -$70.34M↓ | -$62.02M↑ | -$62.23M |
| Net Income | -$94.47M↓ | -$84.83M↓ | -$67.61M↓ | -$59.73M↓ | -$59.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-117.84%
Volume
Today's trading volume
2.27M
Recent News
Street Calls of the Week
Monday - Lumentum Holdings What’s the full story? Evercore initiates Lumentum Lumentum Holdings Inc (NASDAQ:LITE) at Outperform with an $1,100 target. The AI revolution has a supply-chain coronary: silicon processors run fast, but data can’t move between them. Connecting these compute clusters requires Indium Phosphide lasers—a scarce, capital-intensive material where demand outpaces supply by 30%. LITE holds the choke point, shifting pricing power and margin upstream to vertically integrated in
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO
EyePoint just saw its assessed fair value reset sharply, dropping from US$40.54 to US$25.91, which signals a major rethink of where analysts see the stock’s long term potential. This reset lines up with a split analyst view after the LUGANO Phase 3 miss, wide ranging new price targets, and fresh questions about Duravyu and execution risk. In the sections ahead, you will see what is driving the changing narrative around EyePoint and how to track the story as new data arrives. Stay updated as...
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, GitLab, GLOBAL FOUNDRIES, Martin Marietta Materials, Rocket Lab USA, Strategy, Toast, Tower Semiconductor, and More
Markets took a beating Tuesday as war tensions, surging oil, and the September curse hammered stocks, bonds, and gold all at once. Find out which stocks Wall Street upgraded, downgraded, or initiated fresh coverage on as analysts scramble to reposition heading into a brutal stretch.
These 2 Stocks Are Setting Off Technical Alarm Bells with $1,000+ Price Tags. Here’s the Company I’d Bet on for the Long Term.
Graham Holdings (GHC) was a bearish price surprise on Monday, down 2.2%. At the same time, Biglari Holdings (BH.A) was a bullish price surprise, up 3.56%. Both holding companies have diversified businesses. The bear is the bet.